Cargando…
Nonclinical Development of SRK-181: An Anti-Latent TGFβ1 Monoclonal Antibody for the Treatment of Locally Advanced or Metastatic Solid Tumors
Checkpoint inhibitors offer a promising immunotherapy strategy for cancer treatment; however, due to primary or acquired resistance, many patients do not achieve lasting clinical responses. Recently, the transforming growth factor-β (TGFβ) signaling pathway has been identified as a potential target...
Autores principales: | Welsh, Brian T., Faucette, Ryan, Bilic, Sanela, Martin, Constance J., Schürpf, Thomas, Chen, David, Nicholls, Samantha, Lansita, Janice, Kalra, Ashish |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8135237/ https://www.ncbi.nlm.nih.gov/pubmed/33739172 http://dx.doi.org/10.1177/1091581821998945 |
Ejemplares similares
-
Structural basis of specific inhibition of extracellular activation of pro- or latent myostatin by the monoclonal antibody SRK-015
por: Dagbay, Kevin B., et al.
Publicado: (2020) -
Biomarkers for nonclinical infusion reactions in marketed biotherapeutics and considerations for study design
por: Mease, Kirsten M., et al.
Publicado: (2017) -
A Randomized Phase 1 Safety, Pharmacokinetic and Pharmacodynamic Study of the Novel Myostatin Inhibitor Apitegromab (SRK-015): A Potential Treatment for Spinal Muscular Atrophy
por: Barrett, Doreen, et al.
Publicado: (2021) -
Preclinical Safety Assessment and Toxicokinetics of Apitegromab, an Antibody Targeting Proforms of Myostatin for the Treatment of Muscle-Atrophying Disease
por: Welsh, Brian T., et al.
Publicado: (2021) -
Accuracy of the SRK/T Formula in Pediatric Cataract Surgery
por: Irfani, Irawati, et al.
Publicado: (2023)